Last reviewed · How we verify
Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease
Approved treatments
- Beyfortus · National Institute of Allergy and Infectious Diseases (NIAID)
- BEYFORTUS · ASTRAZENECA AB
- Beyfortus · AstraZeneca
BEYFORTUS is a monoclonal antibody that targets RSV.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease treatment landscape brief
- Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease treatment updates RSS
Frequently asked questions about Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease
What drugs treat Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease?
Tracked treatments include Beyfortus, BEYFORTUS.
What is the treatment for Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease?
Standard treatment for Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease includes Beyfortus, BEYFORTUS. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease patent cliff · Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease CI report
- Treatment: Beyfortus · National Institute of Allergy and Infectious Diseases (NIAID)
- Treatment: BEYFORTUS · ASTRAZENECA AB
- Treatment: Beyfortus · AstraZeneca
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing